Wyrick S D, Voorstad P J, Cocolas G, Hall I H
J Med Chem. 1984 Jun;27(6):768-72. doi: 10.1021/jm00372a011.
The apparent benefit of limiting serum cholesterol and triglyceride levels either by dietary restriction or drug therapy has prompted work in our laboratories toward development of a suitable antihyperlipidemic agent. We have demonstrated the antihyperlipidemic activity of a series of phthalimide derivatives in rodents to be significantly greater than that of clofibrate at a dose of 20 mg/(kg day), intraperitoneally. Here we report the synthesis and biological evaluation of a series of indazolone derivatives, which are heterocycles that are structurally related to the phthalimides . In general, structure-activity relationships within the phthalimide series may be extended to the indazolones . While indazolone itself is only moderately active, N1-carbethoxy substitution produced a more active compound. Substitution of the N2 position with an n-butyl group afforded the most active compound, as also seen in the phthalimide series. Aromatic substitution with electron-releasing and -withdrawing groups lessened the antihyperlipidemic activity.
通过饮食限制或药物治疗来限制血清胆固醇和甘油三酯水平所带来的明显益处,促使我们实验室开展工作,致力于开发一种合适的抗高血脂药物。我们已证明,一系列邻苯二甲酰亚胺衍生物在啮齿动物体内的抗高血脂活性,在腹膜内给予20毫克/(千克·天)的剂量时,显著高于氯贝丁酯。在此,我们报告一系列吲唑酮衍生物的合成及生物学评价,这些吲唑酮是与邻苯二甲酰亚胺结构相关的杂环化合物。一般而言,邻苯二甲酰亚胺系列内的构效关系可能延伸至吲唑酮。虽然吲唑酮本身活性仅为中等,但N1-乙氧羰基取代产生了一种活性更高的化合物。用正丁基取代N2位得到了活性最高的化合物,这在邻苯二甲酰亚胺系列中也有体现。用供电子和吸电子基团进行芳基取代会降低抗高血脂活性。